Physician profile
Gurbinder Brar
NPI 1861569022
$589.35
in general payments reported to CMS, 2019-2025
16 companies · $56.81 in 2025
The $56.81 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94.95 · 2020: $20.13 · 2021: $59.05 · 2022: $13.62 · 2023: $185 · 2024: $160 · 2025: $56.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $402.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $401.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $160.09 | 2023-2024 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $59.05 | 2021 | |
| Pfizer INC. | $40.52 | 2024-2025 | |
| Glaxosmithkline, LLC. | $40.15 | 2019-2025 | Trelegy Ellipta |
| Exact Sciences Corporation | $38.45 | 2023-2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $32.38 | 2019 | |
| Inspire Medical Systems, INC. | $32.13 | 2024 | Inspire |
| Sanofi Pasteur INC. | $29.53 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.56 | 2022-2023 | Xifaxan |
| Novo Nordisk INC | $20.94 | 2024 | Rybelsus, Ozempic |
| Allergan, INC. | $20.13 | 2020 | |
| Galderma Laboratories, L.P. | $19.94 | 2019 | |
| Eisai INC. | $19.23 | 2025 | |
| Esperion Therapeutics, INC. | $18.37 | 2024 | Nexletol |
| Novartis Pharmaceuticals Corporation | $17.12 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $12.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gurbinder Brar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.